Navigation Links
BioNanomatrix Appoints Gary Zweiger, Ph.D., as Vice President of Business Development
Date:12/2/2008

--Appointment Expands Leadership Team and Strengthens Commercial Focus--

PHILADELPHIA, Dec. 2 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough nanoscale platforms for molecular diagnostics, personalized medicine and biomedical research, today announced the appointment of Gary Zweiger, Ph.D., as vice president of business development. Dr. Zweiger has over a decade of strategic business development experience with leading biotechnology and genomics companies. He will focus on expanding BioNanomatrix's commercial and research partnerships for its breakthrough nanoscale whole genome technology platform in multiple markets, including research, diagnostics and personalized medicine.

"Gary's background and experience are close to ideal for our newly created senior business development position, and we are very pleased to have him on board," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix. "Gary's scientific expertise is directly relevant to our end-user markets and his extensive business development and alliance management experience should be invaluable as we expand our network of collaborations and commercial partnerships."

BioNanomatrix is applying its expertise in nanochips, nanodevices and nanosystems to develop its platform technology providing fast, comprehensive and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Among its current development efforts is a federally funded project in partnership with Complete Genomics Inc. for very low-cost sequencing of the human genome.

"This is an exciting time to join BioNanomatrix as the company is advancing a potentially transformative single-molecule, whole genome sorting and imaging technology that will enable scientists to analyze clinically relevant DNA sequence variation, copy number and positional information, and to do so much faster, more cost-effectively and with far better resolution than existing methods," said Dr. Zweiger. "There are many possible applications for our technology, and I look forward to working with the BioNanomatrix team to expand the company's growing list of partnerships and help establish new opportunities for growth."

Prior to joining BioNanomatrix, Dr. Zweiger was senior director of business development at Affymetrix, where he managed collaborations, developed new business opportunities and secured revenue-generating research partnerships. Previously, he was director of business development for Applied Biosystems' Cell and Molecular Biology division, where he managed collaborations and business development activities for the company's PCR, DNA sequencing, RNA interference and cell biology businesses. Prior to Applied Biosystems, Dr. Zweiger was at Agilent Technologies, where he held positions of increasing responsibility, directing efforts to identify, assess and secure new business opportunities. Earlier in his career, Dr. Zweiger served as a strategic advisor and consultant to biotechnology and genomics companies and to the financial community. He has published a general audience book on sequencing the human genome, authored numerous scientific publications and holds seven patents. Dr. Zweiger received a Ph.D. in genetics and a B.S. in biological sciences from Stanford University and completed a post-doctoral fellowship in molecular oncology at Genentech Inc.

About BioNanomatrix

BioNanomatrix isdeveloping breakthrough nanoscale whole genome imaging and analytic platforms for applications in genetic diagnostics, personalized medicine and biomedical research. The company is applying its expertise in nanochips, nanodevices and nanosystems to develop its patented platform technology to provide fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information with sensitivity at the single-molecule level. Its current development efforts include a federally funded project to sequence the human genome at a cost of $100. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit: www.BioNanomatrix.com.

    Contact:
    Barbara Lindheim
    GendeLLindheim BioCom Partners
    212 918-4650


'/>"/>
SOURCE BioNanomatrix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WorldHeart Appoints David Pellone Chief Financial Officer
2. Novo Nordisk Appoints New Leader of North American Business
3. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
4. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
5. Resonant Medical Appoints New Vice President of Global Sales
6. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
7. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
8. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
9. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
10. Governor Rendell Appoints Members of Chronic Care Commission as Part of Prescription for PA
11. Adlyfe Appoints Roxanne Duan as Vice President of Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology: